Search Within

Jose T Baselga

  1. "Survivorship Research"
Formats
  1. Meeting Abstract (44)
  2. Journal Article (41)
  3. Conference Paper (2)
  4. Research Letter (1)
Groups
  1. Survivorship Research (88)
  2. Department of Medicine (87)
  3. Solid Tumor Oncology Division (87)
  4. Breast Medicine Service (82)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (52)
  6. GSK Faculty (39)

More Groups

People
  1. Clifford Hudis (57)
  2. Larry Norton (41)
  3. David Hyman (26)
  4. Michael Berger (23)
  5. Andrew Seidman (20)
  6. Chau Dang (20)

More People

Years
  1. 2020 (2)
  2. 2019 (4)
  3. 2018 (6)
  4. 2017 (16)
  5. 2016 (11)
  6. 2015 (16)

More Years

Publications
  1. Journal of Clinical Oncology (24)
  2. Cancer Research (15)
  3. Annals of Oncology (7)
  4. Blood (6)
  5. Breast Cancer Research and Treatment (4)
  6. JCO Precision Oncology (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (27)
  2. American Association for Cancer Research (20)
  3. Oxford University Press (9)
  4. Elsevier Inc. (7)
  5. American Society of Hematology (6)
  6. Nature Publishing Group (5)

More Publishers

Results (88)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I, open-label study evaluating the safety and tolerability of LJM716, BYL719 and trastuzumab in patients with metastatic HER2+ breast cancer
    Meeting Abstract

    Shah, P. D.; Chandarlapaty, S.; Ulaner, G.; Zamora, S.; Sterlin, V.; Iasonos, A.; Dickler, M. N.; Moynahan, M. E.; Hudis, C. A.; Baselga, J.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Caravella, B. A.; Datko, F. M.; Zamora, S.; Comen, E.; Gilewski, T.; Sugarman, S. M.; D'Andrea, G.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • A phase I/II study of neratinib plus temsirolimus in HER2+ metastatic breast cancer reveals ongoing HER2 pathway dependence in many patients despite several lines of HER2 targeted therapy
    Meeting Abstract

    Gajria, D.; Modi, S.; Saura, C.; Sakr, R.; Solano, K.; Won, H.; Pannu, H.; Patil, S.; Lake, D.; Traina, T.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders
    Journal Article

    Hyman, D. M.; Diamond, E. L.; Vibat, C. R. T.; Hassaine, L.; Poole, J. C.; Patel, M.; Holley, V. R.; Cabrilo, G.; Lu, T. T.; Arcila, M. E.; more...
    Cancer Discovery (2015)

    Fulltext@MSK | Save
  • Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
    Journal Article

    Dang, C.; Iyengar, N.; Datko, F.; D'Andrea, G.; Theodoulou, M.; Dickler, M.; Goldfarb, S.; Lake, D.; Fasano, J.; Fornier, M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase I trial of daily PI3K alpha inhibitor BYL719 plus letrozole (L) or exemestane (E) for patients (pts) with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Modi, S.; Datko, F. M.; Moynahan, M. E.; Zamora, S.; D'Andrea, G.; Lake, D.; Goldfarb, S. B.; Patil, S.; Singh, S.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Monitoring PIK3CA mutant allele fraction (AF) in cell-free DNA (cfDNA) in metastatic breast cancer (MBC) patients treated with PI3K alpha-inhibitor plus letrozole (L) or exemestane (E)
    Meeting Abstract

    Moynahan, M. E.; Sung, P.; Asham, M.; Zamora, S.; Shah, P. D.; Modi, S.; Lake, D.; D'Andrea, G.; Goldfarb, S. B.; Chandarlapaty, S.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Phase II feasibility study of paclitaxel (T) with trastuzumab (H) and lapatinib (L) for node-negative, HER2-positive breast cancer (BC)
    Meeting Abstract

    Iyengar, N. M.; Fornier, M. N.; Sugarman, S.; Theodoulou, M.; Troso-Sandoval, T. A.; D'Andrea, G.; Drullinsky, P.; Fasano, J.; Gajria, D.; Goldfarb, S. B.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A virtual consult service to optimize clinical trial participation in patients with metastatic breast cancer
    Meeting Abstract

    Cadoo, K. A.; Shah, P. D.; Charen, A. S.; Bromberg, J.; Comen, E. A.; D'Andrea, G.; Dang, C. T.; Gilewski, T.; Gucalp, A.; Lake, D.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A phase III randomized, double-blind, trial comparing sorafenib plus capecitabine versus placebo plus capecitabine in the treatment of locally advanced or metastatic HER2-negative breast cancer (resilience)
    Meeting Abstract

    Baselga, J.; Zamagni, C.; Gomez, P.; Bermejo, B.; Nagai, S.; Melichar, B.; Chan, A.; Mangel, L.; Bergh, J.; Costa, F. P.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save